Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP932325.RA2wPsMefC9YHhnqALj5DqZLVmsdWNiGN18A-ywbcFl6o130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP932325.RA2wPsMefC9YHhnqALj5DqZLVmsdWNiGN18A-ywbcFl6o130_assertion type Assertion NP932325.RA2wPsMefC9YHhnqALj5DqZLVmsdWNiGN18A-ywbcFl6o130_head.
- NP932325.RA2wPsMefC9YHhnqALj5DqZLVmsdWNiGN18A-ywbcFl6o130_assertion description "[The MAL gene, which has been shown to confer resistance to cancer therapy, was most highly overexpressed in short-term survivors (3-fold compared with long-term survivors, and 29-fold compared with early-stage cases).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP932325.RA2wPsMefC9YHhnqALj5DqZLVmsdWNiGN18A-ywbcFl6o130_provenance.
- NP932325.RA2wPsMefC9YHhnqALj5DqZLVmsdWNiGN18A-ywbcFl6o130_assertion evidence source_evidence_literature NP932325.RA2wPsMefC9YHhnqALj5DqZLVmsdWNiGN18A-ywbcFl6o130_provenance.
- NP932325.RA2wPsMefC9YHhnqALj5DqZLVmsdWNiGN18A-ywbcFl6o130_assertion SIO_000772 15897565 NP932325.RA2wPsMefC9YHhnqALj5DqZLVmsdWNiGN18A-ywbcFl6o130_provenance.
- NP932325.RA2wPsMefC9YHhnqALj5DqZLVmsdWNiGN18A-ywbcFl6o130_assertion wasDerivedFrom befree-20150227 NP932325.RA2wPsMefC9YHhnqALj5DqZLVmsdWNiGN18A-ywbcFl6o130_provenance.
- NP932325.RA2wPsMefC9YHhnqALj5DqZLVmsdWNiGN18A-ywbcFl6o130_assertion wasGeneratedBy ECO_0000203 NP932325.RA2wPsMefC9YHhnqALj5DqZLVmsdWNiGN18A-ywbcFl6o130_provenance.